In Silico Antibody Development with AlphaBind using NVIDIA BioNeMo and AWS HealthOmics
Summary: In-silico antibody development is revolutionizing the way therapeutic antibodies are designed and developed. This approach uses computational methods to simulate and predict antibody behavior, significantly speeding up the development process. A-Alpha Bio and NVIDIA have collaborated to create AlphaBind, a deep-learning model that optimizes antibody-antigen binding affinity using large-scale data and machine learning. This article explores how AlphaBind, powered by NVIDIA BioNeMo and AWS HealthOmics, is transforming the field of antibody development....